The 10,000-step target came from a pedometer's brand name, not from research

The 10,000-step goal has no research origin. It most likely comes from the trade name of a pedometer sold in 1965 by the Yamasa Clock and Instrument Company in Japan, called Manpo-kei — which translates as "10,000 steps meter" [s3]. The largest synthesis of the evidence, published in The Lancet Public Health in 2025, found that the association between daily steps and most health outcomes bends at roughly 5,000 to 7,000 steps a day, not at 10,000 [s1].

That is not the same as saying 10,000 steps is wrong, or that walking more than 7,000 is pointless. It is a narrower and more specific claim: the number that ended up printed on the default screen of almost every fitness tracker was never derived from a study of health outcomes, and the studies that have since been done do not single it out.

Where the number actually came from

The authors of a 2019 cohort study in JAMA Internal Medicine put it plainly in their introduction: a common goal of 10,000 steps a day "has been perpetuated by the lay press and is often used as the default by software programs on wearables and smartphones", while "the origin of the goal of 10 000 steps per day is unclear" [s3]. Their best account is the Manpo-kei pedometer [s3]. It is a marketing name that became a public health target by repetition.

What the dose-response evidence shows

The 2025 review searched PubMed and CINAHL for prospective studies of device-measured daily steps published between 1 January 2014 and 14 February 2025, and included 57 studies from 35 cohorts in the systematic review, with 31 studies from 24 cohorts entering the meta-analyses [s1]. For all-cause mortality, cardiovascular disease incidence, dementia and falls, the association was inverse and non-linear, with inflection points at around 5,000 to 7,000 steps per day [s1]. For cardiovascular mortality, cancer incidence, cancer mortality, type 2 diabetes incidence and depressive symptoms, it was inverse and linear [s1].

Compared with 2,000 steps per day, 7,000 steps per day was associated with a 47% lower risk of all-cause mortality (hazard ratio 0.53, 95% CI 0.46–0.60, from 14 studies), a 25% lower risk of cardiovascular disease incidence, a 47% lower risk of cardiovascular disease mortality, a 37% lower risk of cancer mortality, a 14% lower risk of type 2 diabetes, a 38% lower risk of dementia, a 22% lower risk of depressive symptoms and a 28% lower risk of falls [s1]. Cancer incidence showed a non-significant 6% lower risk [s1].

Those numbers carry very different weights. The mortality estimate pools 14 studies; the dementia estimate pools two, and the cancer incidence estimate pools two [s1]. The authors graded certainty as moderate for most outcomes, low for cardiovascular mortality, cancer incidence and physical function, and very low for falls [s1]. Their own conclusion is that "10 000 steps per day can still be a viable target for those who are more active", while 7,000 "might be a more realistic and achievable target for some" [s1].

The earlier pooled analysis found the same shape, and an age split

A 2022 meta-analysis in the same journal harmonised participant-level data from 15 studies — seven published, eight unpublished — covering 47,471 adults and 3,013 deaths over a median 7.1 years of follow-up [s2]. Median steps per day ran from 3,553 in the lowest quartile to 10,901 in the highest [s2]. Compared with the lowest quartile, the adjusted hazard ratio for death was 0.60 in the second quartile, 0.55 in the third and 0.47 in the fourth [s2].

The interesting part is where the curve flattened. Among adults aged 60 and older, risk fell with increasing steps until 6,000 to 8,000 steps per day; among adults under 60, until 8,000 to 10,000 [s2]. The threshold, in other words, is not one number. It moves with age.

That analysis also tested whether walking faster mattered independently of walking more. After adjusting for total daily steps, the association between higher stepping rates and mortality was attenuated. It remained statistically significant for a peak 30-minute cadence (HR 0.67, 95% CI 0.56–0.83) and a peak 60-minute cadence (0.67, 0.50–0.90), but not for time spent walking at 40 steps per minute or faster (1.12, 0.96–1.32) or at 100 steps per minute or faster (0.86, 0.58–1.28) [s2].

The cohort that first put a number on it

The 2019 JAMA Internal Medicine study followed 16,741 women in the Women's Health Study, mean age 72.0 years, who wore accelerometers during waking hours for seven days between 2011 and 2015 [s3]. Their mean step count was 5,499 per day [s3]. Over a mean 4.3 years of follow-up, 504 died [s3]. Across quartiles with median counts of 2,718, 4,363, 5,905 and 8,442 steps, adjusted hazard ratios for mortality were 1.00, 0.59, 0.54 and 0.42 [s3]. Mortality rates decreased progressively before levelling at approximately 7,500 steps per day [s3].

What this does and does not establish

Every one of these findings is observational. People who walk 8,000 steps a day differ from people who walk 3,000 in ways that no statistical adjustment fully removes — including in ways that cause low step counts rather than result from them, since illness reduces walking. None of these studies randomised anyone to a step count, and none can say that adding steps causes the risk reduction observed.

What they establish with reasonable confidence is the shape. The steepest part of the curve is at the bottom. Moving from a very low step count to a moderate one is associated with most of the difference in risk that is visible in the data; moving from moderate to high is associated with less, and the confidence intervals widen as the counts rise, because fewer people are up there.

The practical consequence is that the number on the tracker matters less than where a person is starting from. A default target set by a 1965 pedometer's brand name is not evidence of anything. Neither, though, is it evidence that 10,000 steps is harmful or useless — the 2025 review is explicit that it remains a viable target for the already-active [s1]. The claim that fails is the narrower one: that 10,000 is a scientifically derived threshold below which benefit does not accrue. The data say benefit accrues well below it.

This article is informational and is not medical advice.

Sources

• Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis — The Lancet Public Health, 2025-07-23
• Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts — The Lancet Public Health, 2022-03-02
• Association of Step Volume and Intensity With All-Cause Mortality in Older Women — JAMA Internal Medicine, 2019-05-29